# US 2009/0023753 A1 · 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0023753 A1
- Document ID: US20090023753A1
- Status: Published application
- Kind: A1
- Application number: 11/885,104
- Filed: 2006-02-24
- Published: 2009-01-22
- Earliest claimed: 2005-03-04
- Assignees: Bayer HealthCare LLC
- Inventors: Chih-Yuan Chuang; Philip Wickens; Zhengiu Hong; Catherine Brennan; Julie A. Dixon; Harold C.E. Kluender; Charles Kreiman; Ellalahewage Kumarasinghe
- Web page: https://patentgrep.com/patent/US20090023753A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel 1,3-thiazole-5-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

## Claims

### Claim 1

A compound of formula (I)
wherein
Ar is selected from the group consisting of
X is CH or N;
R1 is selected from the group consisting of
H,
halogen,
wherein
R1-2 is selected from the group consisting of
H,
(C1-C4)alkyl,
wherein said (C1-C4)alkyl can be substituted with 0, 1, or 2 groups independently selected from hydroxy,
(C1-C4)alkylamino,
(C1-C4)acyloxy,
(C1-C4)alkoxy, and
(C2-C4)alkoxy substituted with 0, 1 or 2 (C1-C4)alkoxy groups,
5- or 6-membered heteroaryl,
and
phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
and
wherein said (C1-C4)alkyl is independently optionally substituted with F up to the perfluoro level;
R1-3 is H or (C1-C4)alkyl;
R1-4, R1-5 and R1-6 are selected from the group consisting of
H,
indan-5-yl,
phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
5- or 6-membered heteroaryl substituted with 0, 1 or 2 groups selected from the group consisting of
cyano,
halo,
nitro,
(C1-C4)alkyl,
wherein said (C1-C4)alkyl is optionally substituted with 0, 1, or 2 groups selected
from
(C1-C4)alkylamino,
(C1-C4)acyloxy,
(C1-C4)alkoxy,
and
(C2-C4)alkoxy substituted with up to 0, 1 or 2 (C1-C4)alkoxy groups,
(C3-C6)cycloalkyl substituted with 0, 1 or 2 groups selected from (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo,
and
(C1-C6)alkyl,
wherein said (C1-C6)alkyl is independently substituted with 0 or 1 group selected from the group consisting of
NH2,
(C1-C4)alkoxy,
(C2-C4)alkoxy independently substituted with 0, 1, 2 or 3 (C1-C4)alkoxy and OH groups,
and
independently optionally substituted with fluorine up to the perfluoro level,
carboxyl,
(C1-C4)alkoxycarbonyl
(C1-C4)alkylamino,
aminocarbonyl,
(C1-C4)alkylsulfonyl,
phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano, 5- or 6-membered heteroaryl independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy,
cyano, halo, and nitro
and
heterocyclyl independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo,
and
wherein said (C1-C6)alkyl is independently substituted with 0, 1 or 2 OH or halo groups,
and
wherein said (C1-C6)alkyl is independently optionally substituted with F up to the perfluoro level;
and
R1-3 and R1-4, R1-3 and R1-5, and R1-3 and R1-6, when attached to the same nitrogen atom, may form, together with the N atom to which they are attached, a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, morpholinyl, thiomorpholinyl and piperizinyl optionally substituted on N with (C1-C4)alkyl,
R1-7 is independently selected from the group consisting of (C1-C4)alkyl,
wherein said (C1-C4)alkyl is substituted with 0, 1 or 2 groups selected from the group consisting of
(C1-C4)alkylamino,
(C1-C4)acyloxy,
(C1-C4)alkoxy,
and
(C2-C4)alkoxy substituted with 0, 1 or 2
(C1-C4)alkoxy groups;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein
Ar is selected from the group consisting of
X is CH;
R1 is selected from the group consisting of
and
wherein
R1-3 is H or (C1-C4)alkyl,
R1-5 and R1-6 are selected from the group consisting of
H,
indan-5-yl,
phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
5- or 6-membered heteroaryl substituted with 0, 1 or 2 groups selected from the group consisting of
cyano,
halo,
nitro,
(C1-C4)alkyl,
wherein said (C1-C4)alkyl is optionally substituted with 0, 1, or 2 groups selected from
(C1-C4)alkylamino,
(C1-C4)acyloxy,
(C1-C4)alkoxy,
and
(C2-C4)alkoxy substituted with up to 0, 1 or 2 (C1-C4)alkoxy groups;
(C3-C6)cycloalkyl substituted with 0, 1 or 2 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo;
and
(C1-C6)alkyl,
wherein said (C1-C6)alkyl is independently substituted with 0 or 1 group selected from the group consisting of
NH2,
(C1-C4)alkoxy,
(C2-C4)alkoxy independently substituted with 0, 1, 2 or 3 (C1-C4)alkoxy and OH groups,
and
independently optionally substituted with fluorine up to the perfluoro level,
carboxyl,
(C1-C4)alkoxycarbonyl
(C1-C4)alkylamino,
aminocarbonyl,
(C1-C4)alkylsulfonyl,
phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
5- or 6-membered heteroaryl independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, cyano, halo, and nitro
and
heterocyclyl is independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo,
and
wherein said (C1-C6)alkyl is independently substituted with 0, 1 or 2 OH or halo groups,
and
wherein said (C1-C6)alkyl is independently optionally substituted with F up to the perfluoro level;
and
R1-3 and R1-5, and R1-3 and R1-6, when attached to the same nitrogen atom, may form, together with the N atom to which they are attached, a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, morpholinyl, thiomorpholinyl and piperizinyl optionally substituted on N with (C1-C4)alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein
Ar is
X is CH;
R1 is selected from
and
wherein
R1-3 is H,
R1-5 is (C1-C6)alkyl,
wherein said (C1-C6)alkyl is independently substituted with 0 or 1 group selected from
(C1-C4)alkoxy,
(C2-C4)alkoxy independently substituted with 0, 1, or 2 (C1-C4)alkoxy and OH groups,
and
independently optionally substituted with fluorine up to the perfluoro level,
and
wherein said (C1-C6)alkyl is independently substituted with 0, 1 or 2 OH or halo groups,
and
wherein said (C1-C6)alkyl is independently optionally substituted with F up to the perfluoro level;
R1-6 is selected from the group
H,
and
(C1-C6)alkyl,
wherein said (C1-C6)alkyl is independently substituted with 0 or 1 group selected from
(C1-C4)alkoxy,
(C2-C4)alkoxy independently substituted with 0, 1, 2 or 3 (C1-C4)alkoxy and OH groups,
and
independently optionally substituted with fluorine up to the perfluoro level,
and
wherein said (C1-C6)alkyl is independently substituted with 0, 1 or 2 OH or halo groups,
and
wherein said (C1-C6)alkyl is independently optionally substituted with F up to the perfluoro level;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of claim 1 for the treatment or prevention of disorders.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, additionally comprising at least one pharmaceutically acceptable carrier or excipient.

### Claim 7 (depends on 5)

A pharmaceutical composition of claim 5 for the treatment or prevention of cancer.

### Claim 8 (depends on 1, 6)

A process for preparing the pharmaceutical composition of claim 6, comprising combining at least one compound according to claim 1 with at least one pharmaceutically acceptable carrier or excipient and bringing the resulting combination into a form suitable for said pharmaceutical composition.

### Claim 9 (depends on 1)

A use of a compound of claim 1 for manufacturing a pharmaceutical composition for the treatment or prevention of a disease.

### Claim 10 (depends on 9)

The use of claim 9, wherein the disease is cancer.

### Claim 11 (depends on 1)

A method of treating a disease or condition in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease or condition is cancer.
